New immune therapy trial offers hope for Tough-to-Treat breast cancer
Disease control
Completed
This study tested a two-part immunotherapy for people with advanced breast cancer that had spread or returned after standard treatments failed. The treatment combined a personalized cell-based vaccine (SV-BR-1-GM) with an immune-boosting drug (retifanlimab). The main goals were t…
Phase: PHASE1, PHASE2 • Sponsor: BriaCell Therapeutics Corporation • Aim: Disease control
Last updated Apr 02, 2026 04:26 UTC